Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0F6YW
|
|||
| Former ID |
DNCL002739
|
|||
| Drug Name |
Sagopilone
|
|||
| Synonyms |
Sagopilone; ZK-EPO; 305841-29-6; UNII-KY72JU32FO; KY72JU32FO; DE-03757; ZK-219477; EPO-477; SH-Y03757A; ZK epothilone; Sagopilone [USAN:INN]; Sagopilone (USAN/INN); SCHEMBL423579; CHEMBL2304041; SH Y03757A; Bay 86-5302; ZINC3964449; DB12391; SH-Y-03757; BAY-86-5302; AN-28960; DE 03757; ZK 219477; D09721; 841S296; (1S,3S,7S,10R,11S,12S,16R)-10-allyl-7,11-dihydroxy-8,8,12,16-tetramethyl-3-(2-methyl-1,3-benzothiazol-5-yl)-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65] | Phase 2 | [1] | |
| Ovarian cancer [ICD-11: 2C73; ICD-10: C56] | Phase 2 | [1] | ||
| Prostate cancer [ICD-11: 2C82.0] | Phase 2 | [1] | ||
| Company |
Bayer HealthCare Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C30H41NO6S
|
|||
| Canonical SMILES |
CC1CCCC2(C(O2)CC(OC(=O)CC(C(C(=O)C(C1O)CC=C)(C)C)O)C3=CC4=C(C=C3)SC(=N4)C)C
|
|||
| InChI |
1S/C30H41NO6S/c1-7-9-20-27(34)17(2)10-8-13-30(6)25(37-30)15-22(19-11-12-23-21(14-19)31-18(3)38-23)36-26(33)16-24(32)29(4,5)28(20)35/h7,11-12,14,17,20,22,24-25,27,32,34H,1,8-10,13,15-16H2,2-6H3/t17-,20+,22-,24-,25-,27-,30+/m0/s1
|
|||
| InChIKey |
BFZKMNSQCNVFGM-UCEYFQQTSA-N
|
|||
| CAS Number |
CAS 305841-29-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00598507) Phase II Trial Of ZK-EPO (ZK 219477) (Sagopilone) In Metastatic Melanoma. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.